Related Experiment Video
Updated: Jul 29, 2025
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Aerosolized Antibiotics to Manage Ventilator-Associated Infections: A Comprehensive Review
Pavlos Myrianthefs1, George E Zakynthinos2, Vasiliki Tsolaki3
1"Agioi Anargyroi" General Hospital, School of Health Sciences, Department of Nursing, National and Kapodistrian University of Athens, 14564 Athens, Greece.
Background:
Ventilator-associated lower respiratory tract infectious complications in critically ill patients cover a wide spectrum of one disease process (respiratory infection), initiating from tracheal tube and/or tracheobronchial colonization, to ventilator associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP). VAP occurence has been associated with increased intensive care unit (ICU) morbidity (ventilator days, as well as length of ICU and hospital stay) and ICU mortality. Therefore, treatments that aim at VAP/VAT incidence reduction are a high priority.
Aim:
The aim of the present review is to discuss the current literature concerning two major aspects: (a) can aerosolized antibiotics (AA) administered in a pre-emptive way prevent the occurrence of ventilator-associated infections? and (b) can VAT treatment with aerosolized avert the potential evolution to VAP?
Results:
There were identified eight studies that provided data on the use of aerosolized antibiotics for the prevention of VAT/VAP. Most of them report favorable data on reducing the colonisation rate and the progression to VAP/VAT. Another four studies dealt with the treatment of VAT/VAP. The results support the decrease in the incidence to VAP transition and/or the improvement in signs and symptoms of VAP. Moreover, there are concise reports on higher cure rates and microbiological eradication in patients treated with aerosolized antibiotics. Yet, differences in the delivery modality adopted and resistance emergence issues preclude the generalisability of the results.
Conclusion:
Aerosolized antibiotic therapy can be used to manage ventilator-associated infections, especially those with difficult to treat resistance. The limited clinical data raise the need for large randomized controlled trials to confirm the benefits of AA and to evaluate the impact on antibiotic selection pressure.
Insights
Aerosolized antibiotics show promise in preventing and treating ventilator-associated infections like pneumonia. Further research is needed to confirm benefits and assess resistance impacts.
Area of Science:
- Critical care medicine
- Infectious diseases
- Pulmonology
Background:
- Ventilator-associated infections (VAI), including ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP), are significant complications in critically ill patients.
- VAP is linked to increased intensive care unit (ICU) morbidity and mortality, making VAP/VAT incidence reduction a priority.
Purpose of the Study:
- To review current literature on aerosolized antibiotics (AA) for preventing ventilator-associated infections.
- To evaluate the efficacy of AA in treating VAT and preventing its progression to VAP.
Main Methods:
- Systematic review of studies investigating aerosolized antibiotics for VAP/VAT prevention and treatment.
- Analysis of data on colonization rates, VAP progression, clinical outcomes, and microbiological eradication.
Main Results:
- Eight studies suggest AA can reduce colonization and progression to VAP/VAT.
- Four studies indicate AA treatment may decrease VAP incidence, improve symptoms, and enhance cure rates.
- Emerging antibiotic resistance and varied delivery methods limit generalizability.
Conclusions:
- Aerosolized antibiotic therapy is a potential management strategy for ventilator-associated infections, particularly drug-resistant cases.
- Limited data necessitates large randomized controlled trials to validate AA benefits and evaluate antibiotic resistance pressures.
More Related Videos
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:23Inhaled Medications
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...